ALK News

Triana Biomedicines tests degradation-first approach in ALK positive lung cancer with TRI-611 pharmadevicenews.com/triana-biomedi… Triana Biomedicines launches TRI-611 trial in ALK lung cancer. Can molecular glue degraders overcome resistance? Read the full analysis. #LungCancer #Oncology #ClinicalTrials #Biotech #DrugDevelopment #PrecisionMedicine #CancerResearch #TargetedTherapy @TrianaBioMedicines

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies In >13,000 tumors, MTAP deletion was found in: ALK 27–45% RET 18–35% EGFR 17–29% 98% co-deleted with CDKN2A. TKI outcomes unchanged ⚠️⚠️ annalsofoncology.org/article/S0923-… #NSCLC #lcsm #EGFR

Sustained CR with Brigatinib with ALK-positive NSCLC harboring the I1171N mutation after Alectinib. Highlights importance of re-biopsy & mutation-directed TKI sequencing. DOI: 10.1155/crom/7372418 #ALK #NSCLC #PrecisionOncology @LungConnectIN @IASLC @SuyogCancer @Bipinesh

Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report frontiersin.org/journals/oncol…

🎉Excited to share safety & efficacy of my Ph 1/2 clinical trial of amivantamab + ALK, ROS, or RET TKIs! ❗️No new safety signals (VTE, ILD, liver tox) seen with combo. IRR universal, but ami dose reduction low (11%) ⭐️ORR=22%, DCR=100% 🔬More translational data coming!! @lcsmchat @OncoAlert @OncLive @OncogeneCancer @ALKPositiveinc @ALKpositiveINT @ALKpositiveINT @ros1cancer @LungCancerEu @LUNGevity @MedwatchKate @IASLC @ASCO @LungCancerRx

⚡️TUNE IN ON MONDAY: Topline pivotal data for TKI pre-treated patients with advanced ALK+ NSCLC from our ALKOVE-1 clinical trial of investigational candidate neladalkib are coming. Join our live webcast & conference call on November 17, 2025 at 8:00am ET. investors.nuvalent.com/2025-11-14-Nuv…

🧬 Rare ALK variants matter. We recently reported a complete response to lorlatinib in a patient with lung adenocarcinoma harboring the rare EML4-ALK fusion variant (E6;A18). Find the case report and a review of the literature in the @JNCCN 👇 doi.org/10.6004/jnccn.…

Beyond Survival: The Psychosocial Toll of Living With ALK-Positive NSCLC physiciansweekly.com/post/beyond-su…?

Low-dose lorlatinib during pregnancy: Yao et al. report a rare, successful case, underscoring potential safety and ongoing concerns. bit.ly/47pWLcT @IHuaXil

Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib dovepress.com/article/downlo…

Retrospective look from Princess Margaret at weight and efficacy/toxicity of ALK TKIs @JTOonline. Higher weight or BSA associated with dose reduction and interruption, weight gain but not associated with efficacy outcomes of PFS or OS. jtocrr.org/article/S2666-…

🚀 Big news in lung cancer treatment! NICE has recommended lorlatinib (Lorviqua) as a first-line option for ALK-positive advanced NSCLC — a once-daily pill that could help over 260 patients in England live longer, better lives. 💊💙 • 🔬 Targeted therapy that delays disease progression and improves quality of life for younger patients with ALK gene mutations. 📖 Read more: nationalhealthexecutive.com/articles/game-… #LungCancerAwareness #ALKPositive #NSCLC #CancerTreatment #Lorlatinib #NICEguidance #Pfizer #HealthcareInnovation @NICEComms @pfizer @ALKPositiveUK

Pooled analysis from ALTA-2 and J-ALTA @LungCaJournal by @TonyMok9 et al shows efficacy of brigatinib after alectinib in #ALK NSCLC: RR 31%, DOR 9.2m, PFS 5.2m, OS 25m. PFS better if ctDNA negative (11 vs 3.5m). lungcancerjournal.info/article/S0169-…

A new data analysis, presented by Dr. Upal Basu Roy at the #WCLC25, followed patients with ALK+ and EGFR+ #NSCLC for 12 months to understand how often and why treatments were changed. Learn more here: lungevity.org/blogs/beyond-t…

EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer aacrjournals.org/cancerimmunolr…

September is Childhood Cancer Awareness Month. At 7, Deliah was diagnosed with ALK+ brain cancer. Now 13, she fights with courage & hope. 💛 Read her story: alkpositive.org/blog/pediatric…

ALK Lung Cancer Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment aacrjournals.org/cancerimmunolr…

Huge thank you to @UpstageLungCanc for supporting our work understanding TKI resistance mechanisms in ALK lung cancer! @break_cancer @kochinstitute upstagelungcancer.org/research/

A review of 36 advanced lung adenocarcinoma cases with unusual ALK fusions reveals alectinib is a viable treatment option, providing valuable guidance for clinicians. bit.ly/3URldhj